Fathima, S., Alsugair, A., Langer, K., Lasho, T., Finke, C., Litzow, M., Matin, A., Durani, U., Torghabeh, M. H., Hogan, W., Shah, M., Go, R., Bartoo, G., Kutzke, J., McCullough, K., Koster, M. J., Warrington, K., Reichard, K., Olteanu, H., Kusne, Y., Palmer, J., Chhabra, S., Riwes, M., McGuirk, J., Krakow, E., Langston, A., Kourelis, T., Dingli, D., Patnaik, M., Alkhateeb, H., Mangaonkar, A. (2025). Upfront therapy with allogeneic hematopoietic stem cell transplantation versus DNA methyltransferase inhibitors in patients with vexas syndrome: A comparative matched cohort efficacy analysis of 39 patients. Blood. https://doi.org/10.1182/blood-2025-981